Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prodrugs: advantage or disadvantage?

J Hammerstein1

  • 1Obstetrics and Gynecology Department, Klinikum Steglitz, Freie Universität Berlin, West Germany.

American Journal of Obstetrics and Gynecology
|December 1, 1990
PubMed
Summary

Knowledge of prohormones remains limited. While prodrugs have longer peak times, this is usually clinically insignificant, but reduced elimination can decrease potency.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Effects of defensive medicine on costs].

Zeitschrift fur arztliche Fortbildung und Qualitatssicherung·2001
Same author

[Medical discretion and data protection in medicine].

Zeitschrift fur arztliche Fortbildung und Qualitatssicherung·2000
Same author

Depression and anxiety symptoms in women at high risk for breast cancer: pilot study of a group intervention.

The American journal of psychiatry·1999
Same author

[Personal experiences of a physician with legal proceedings].

Zeitschrift fur arztliche Fortbildung und Qualitatssicherung·1999
Same author

[Legal liability in failed sterilization from the physician's viewpoint].

Zeitschrift fur arztliche Fortbildung·1995
Same author

[Position of the German Society of Gynecology and Obstetrics on the intended recall of approved CPA-containing drugs].

Gynakologisch-geburtshilfliche Rundschau·1995

Area of Science:

  • Pharmacology and clinical drug use.
  • Drug metabolism and pharmacokinetics.

Background:

  • Limited understanding of prohormone characteristics.
  • Prohormones require biotransformation to active drugs.

Purpose of the Study:

  • To review the pharmacological and clinical implications of prohormone use.
  • To establish guidelines for assessing prodrugs based on pharmacokinetic data.

Main Methods:

  • Review of existing pharmacological and clinical data on prohormones.
  • Analysis of pharmacokinetic parameters including time to peak concentration and area under the curve.
  • Evaluation of biotransformation pathways and their clinical relevance.

Main Results:

  • Prodrugs consistently exhibit longer times to peak plasma concentrations compared to their active drug counterparts.
  • Pharmacokinetic differences limited to the distribution phase suggest bioequivalence.
  • Reduced area under the curve during elimination for prodrugs indicates decreased potency.
  • Altered endocrine actions or side effect profiles are uncommon but possible.

Conclusions:

  • Clinical significance of prolonged peak times for prodrugs is generally minimal.
  • Bioequivalence can often be assumed if pharmacokinetic variations are confined to distribution.
  • Potency assessment requires careful consideration of elimination phase pharmacokinetics.
  • Investigating additional metabolic pathways is crucial when significant differences in endocrine action or side effects are observed.

Related Experiment Videos